Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410163 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
A Phase 2 study of Leukaemia, Lymphocytic, Chronic, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 2
- Study locations
NCT00410163 is a Phase 2 study of Leukaemia, Lymphocytic, Chronic that has completed, run by GlaxoSmithKline. The registered enrollment target is 61 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00410163, a Phase 2 study of Leukaemia, Lymphocytic, Chronic, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 2
- Study locations
Study Summary
To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Ofatumumab 500mg
- DRUG Ofatumumab 1000mg
Study Locations (2)
Texas
- GSK Investigational Site - Houston
Devon
- GSK Investigational Site - Plymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410163
The ClinicalTrials.gov registry entry for NCT00410163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukaemia, Lymphocytic, Chronic appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00410163 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Devon.
Frequently Asked Questions
What is clinical trial NCT00410163 about?
NCT00410163 is a clinical study titled "Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients". To investigate the safety and efficacy of two dose regimes of ofatumumab in combination with chemotherapy in previously untreated patients with B-CLL
What is the current status of trial NCT00410163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2007-01. Estimated completion is 2013-05.
What conditions does trial NCT00410163 study?
This clinical trial studies the following conditions: Leukaemia, Lymphocytic, Chronic.
What interventions are being tested in trial NCT00410163?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Ofatumumab 500mg (DRUG), Ofatumumab 1000mg (DRUG).
Who is sponsoring clinical trial NCT00410163?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00410163 being conducted?
This trial has 2 study locations across Texas, Devon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukaemia, Lymphocytic, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.